All In Biotech

NDA 022264 · Janssen Pharms

Invega Sustenna

Paliperidone Palmitate · Intramuscular

Last checked: Nov 19, 2026Latest source record: Jan 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 31, 2009

Approved uses

5

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 2 recruiting

FAERS reports

28,106

12,195 serious, 1,104 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA SUSTENNA is not approved for use in patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA SUSTENNA is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Feb 14, 2025.

INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia in adults [see Clinical Studies (14.1) ]. Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants [see Clinical Studies (14.2) ]. INVEGA SUSTENNA is an atypical antipsychotic indicated for Treatment of schizophrenia in adults. ( 1 ) Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants. ( 1 )

Mechanism: Paliperidone palmitate is hydrolyzed to paliperidone [see Clinical Pharmacology (12.3) ] . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, the drug's therapeutic effect in schizophrenia could be mediated through a combination of central dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2A ) receptor antagonism.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • INVEGA SUSTENNA · PALIPERIDONE PALMITATE 156MG/ML (156MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AB
  • INVEGA SUSTENNA · PALIPERIDONE PALMITATE 78MG/0.5ML (78MG/0.5ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AB
  • INVEGA SUSTENNA · PALIPERIDONE PALMITATE 234MG/1.5ML (156MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AB
  • INVEGA SUSTENNA · PALIPERIDONE PALMITATE 117MG/0.75ML (117MG/0.75ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AB
  • INVEGA SUSTENNA · PALIPERIDONE PALMITATE 39MG/0.25ML (39MG/0.25ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Paliperidone Palmitate" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use3,059
  • drug ineffective1,783
  • hospitalisation1,667
  • weight increased1,601
  • drug dose omission1,339
  • product dose omission issue1,153
  • gynaecomastia1,065
  • schizophrenia897
  • treatment noncompliance891
  • blood prolactin increased855
  • incorrect dose administered806
  • psychotic disorder740

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20071
20081
200926
2010640
20111,000
20121,510
20131,560
20141,509
20151,658
20161,579
20172,433
20181,719
20191,689
20201,509
20211,601
20222,388
20231,904
20241,855
20251,839
20261,683

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Invega Sustenna (Paliperidone Palmitate)

2024 spending

$1.88B

Beneficiaries

72,112

624,867 claims

Per beneficiary

$26,045

$2,352.66 per unit

View as table
YearSpending
2020$1,372,610,289
2021$1,502,429,444
2022$1,643,708,962
2023$1,821,418,393
2024$1,878,155,857

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 135 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.